Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ: AUPH · Real-Time Price · USD
15.30
+0.01 (0.07%)
Aug 18, 2026, 10:51 AM EDT - Market open
Aurinia Pharmaceuticals Employees
Aurinia Pharmaceuticals had 128 employees as of December 31, 2025. The number of employees decreased by 2 or -1.54% compared to the previous year.
Employees
128
Change (1Y)
-2
Growth (1Y)
-1.54%
Revenue / Employee
$2,433,648
Profits / Employee
$2,454,016
Market Cap
2.04B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 128 | -2 | -1.54% |
| Dec 31, 2024 | 130 | -170 | -56.67% |
| Dec 31, 2023 | 300 | 0 | - |
| Dec 31, 2022 | 300 | 0 | - |
| Dec 31, 2021 | 300 | 6 | 2.04% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| ADMA Biologics | 647 |
| Agios Pharmaceuticals | 540 |
| Nuvation Bio | 305 |
| Stoke Therapeutics | 170 |
| Precigen | 160 |
| Septerna | 123 |
| Taysha Gene Therapies | 99 |
| Mesoblast | 81 |
AUPH News
- 11 days ago - Aurinia Pharmaceuticals price target raised to $16 from $15 at RBC Capital - TheFly
- 12 days ago - Aurinia Pharmaceuticals sees FY26 revenue $315M-$325M, consensus $325.82M - TheFly
- 12 days ago - Aurinia Pharmaceuticals reports Q2 EPS 28c, consensus 24c - TheFly
- 12 days ago - Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress - Business Wire
- 12 days ago - Aurinia Pharmaceuticals Earnings release: Q2 2026 - Filings
- 12 days ago - Aurinia Pharmaceuticals Quarterly report: Q2 2026 - Filings
- 6 weeks ago - Aurinia Pharmaceuticals announces initiation of PRESERVE study - TheFly
- 6 weeks ago - Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis - Business Wire